Originally Posted by mamakay
Is WF10 the same thing as CIO2, anyway?
Yes. It is chlorine dioxide. It also has sodium chlorite in it (which is what chlorine dioxide is acidified from) and peroxide... that is the total matrix of it. It is generally injected. Dioxyclor from my previous post is also chlorine dioxide.
I suspect there are other names and ways companies are trying to patent and/or sell chlorine dioxide and chlorite without actually giving the patient the option to do so at home for a few cents with their own chlorite.
Originally Posted by WildKingdom
I'll have the guts to address it. The articles you link are from 1994 and 1999. I can't find anything recent. So, these small trials are from 12 and 17 years ago, respectively. Nothing new available. My sense- later trials did not amount to anything. If chlorine dioxide was going to amount to anything, Pharma would have jumped on this long ago.
Actually, that isn't the case at all. WF10 is not only still being used and sold, it is being clinically trialled for a wide variety of diseases – and it is also under other names such as Immunokine and Macrokine - sold to Thailand and another country under those names.
So Immunokine is really WF10, which is really chlorine dioxide.
This has been a very interesting research project and I have this thread to thank for it. I may not have discovered this otherwise and with it, it is enough credibility to get my FIL to consider asking his doctor about MMS or one of these chlorine dioxide based therapies for his cancer. Everything happens for a reason, and I knew I was to make it through this thread for a reason. So I thank you all for pushing me so hard... I mean that sincerely.
Here is Immunokine's site: http://immunokine.info/
Here are clinical trials, and I'll start with one published only this year, feb 2011:
WF10 Stimulates NK Cell Cytotoxicity by Increasing LFA-1-Mediated Adhesion to Tumor Cells
The redox-active chlorite-based drug WF10 (Immunokine) was shown to have modulatory effects on both the innate and adaptive immune system in vitro and in vivo. Animal studies suggest that WF10 enhances immunity against tumors. One possible explanation for such an effect is that WF10 stimulates natural killer cell cytotoxicity against malignant cells.
This is macrokine, which is the other name WF10 is sold under, 2004 study:
WF 10: Macrokine, TCDO, tetrachlorodecaoxide.
Oxo completed a trial in 72 cervical cancer patients undergoing radiation therapy in 1989. Results from this trial demonstrated complete remission in 75% of patients receiving WF 10. A follow-up placebo controlled trial in 1996 produced similar results....
WF 10 is approved for use in Thailand under the name IMMUNOKINE in patients with postradiation chronic inflammatory disease including cystitis, proctitis and mucositis. In July 2003, the European examiners informed Oxo Chemie that they intend to grant the company additional patents to the technology platform that supports WF 10, extending the European protection granted in 1992 to cover a much broader range of diseases. The patents will be granted in Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, the Netherlands, Portugal, Spain, Sweden, Switzerland and the UK. Patent claims cover potential treatment for autoimmune disease, organ transplant or graft rejection, lymphoma and inflammation manifested as hepatitis or chronic obstructive pulmonary disease.
That's huge. Note the huge array of different diseases this is purported to treat. And those are just the ones the patent covers.
Phase two clinical trials, Hepatitis C and others:
Cancer trials, 2007